Adocia SA · EURONEXT:ADOC
Adocia SA — Investor Presentation (April 2022)
38 slides from Adocia SA's investor presentation, April 2022

Slide 1: Corporate Presentation April 2022
Corporate Presentation April 2022

Slide 2: Disclaimer
Disclaimer This corporate presentation (the “Presentation”) has The Presentation does not purport to contain well as the trends in the sector in which the Group been prepared by ADOCIA S.A. (the “Company” and, comprehensive or complete information about the operates, may differ materially from those

Slide 3: Highly experienced management team
Highly experienced management team Gérard Soula Olivier Soula Valérie PhD, MBA PhD, MBA Danaguézian Deputy General Manager, President & CEO R&D Director Chief Financial Officer Co-founder Co-founder Jérémy Benattar Michael PharmD, Eng Nguyen Director of Marketing & Head of BD,US Strategy • Co-founde

Slide 4: Executive Summary
Executive Summary Our mission: Discovery and development of therapeutic solutions in the 1 field of metabolic diseases, primarily diabetes and obesity Business model: Licensing to pharma partners after proof-of-concept 2 • Proprietary specialty products based on approved drug • Proprietary technolog

Slide 5: Adocia's partnering models: strategic pillars to ensure cash income sustainability
Adocia’s partnering models: 2 strategic pillars to ensure cash income sustainability Licensing Technological platforms Licensing Proprietary specialty products applied to pharma partner’s based on approved drugs proprietary products • $50m upfront • BioChaperone LisproPartnered • $85m upcoming devel

Slide 6: Proprietary technological platforms with strong IP strategy
Both Adocia’s partnering models are based on proprietary technological platforms with strong IP strategy BioChaperone® AdOral ® AdoShell ® • Pharmaceutical excipient • Pharmaceutical excipient • Hydrogel scaffold • Forms a complex with therapeutic • Enhances proteins/peptides oral route • Encapsulat

Slide 7: Proprietary specialty products based on approved drugs
Proprietary specialty products based on approved drugs 7

Slide 8: Diabetes and Obesity: worldwide chronic pandemics
Diabetes and Obesity: worldwide chronic pandemics 537 million people live with diabetes1 Diabetes is closely linked to obesity 1 in 11 • In the US, 65% of adults with type 13 diabetes and 85% of type 24 are overweight or obese • Several hormones are involved in both diabetes and obesity 1.9 billion

Slide 9: Adocia's vision of metabolic diseases treatment: from hormonal to cell therapies
Adocia’s vision of metabolic diseases treatment: from hormonal to cell therapies Immuno-protective scaffold for islets of Langerhans Oral Delivery of hormones Pluri-hormonal formulations Improved proteins/peptides formulations Adocia is taking on high challenges, that require innovative mindset and

Slide 10: A rich specialty product pipeline to maximize chances of success
A rich specialty product pipeline to maximize chances of success Preclinic Phase 1 Phase 2 Phase 3 Upcoming milestones BC Lispro Phase 3 in China expected in 2022 Ultra-Rapid Insulin Partnered U100 / U200 Phase 3 in USA and Europe expected in 2022* Insulins Combination BC Combo U200 Partnered Phase

Slide 11: BioChaperone Lispro
BioChaperone® Lispro The next best-in-class Rapid Acting Insulin for a tighter glycemic control Corporate Presentation 11

Slide 12: BC Lispro has competitive advantages in the new Ultra-Rapid Insulin class
BC Lispro has competitive advantages in the new Ultra-Rapid Insulin class Post-meal glycaemia in T1D • Better efficacy profile for less hyperglycemia and less hypoglycemia (“Faster-in” / “Faster- out”) vs. comparators AUC0-2h: -61%* • Good tolerance for optimized daily use • Range of strengths (U100

Slide 13: BC Lispro is ready to start phase 3 pivotal program
BC Lispro is ready to start phase 3 pivotal program • Only 3 ultra-rapid insulins will compete in the $9bn1 prandial insulin market, addressing the needs of 34 millions mealtime insulins users (T1D + T2D): BC Lispro • Licensed to Tonghua Dongbao (THDB) for development & commercialization for Chinese

Slide 14: BC Combo, glargine-lispro premix
BC Combo, glargine-lispro premix The best insulin premix Corporate Presentation 14

Slide 15: BC Combo, a unique combination of glargine and lispro
BC Combo, a unique combination of glargine and lispro, the gold standards of basal and prandial insulins BioChaperone® Combo 1 product Once or twice a day U200 fixed ratio (150 U/mL glargine - 50 U/mL lispro) Less hyperglycemia Simple Affordable Less hypoglycemia Limited number of injections

Slide 16: BC Combo is licensed to Tonghua Dongbao in China
BC Combo is licensed to Tonghua Dongbao in China Premix market Tonghua Dongbao deal $2,7bn1 Western Markets: T2D patients • $40m upfront $2,3bn1 • $50m upcoming development Emerging Markets: milestones T1D & T2D ~65% • Double-digit royalties on sales patients Market share in India and China (volume)

Slide 17: Insulin & Amylin analogs combinations M1Pram and BC LisPram
Insulin & Amylin analogs combinations M1Pram and BC LisPram First-in-class combination products, the 5th generation of prandial insulin 17

Slide 18: Amylin hormone is missing in people with diabetes
Amylin hormone is missing in people with diabetes, and it contributes to diabetes dysregulations Meal Pancreas Insulin Normal pattern Level of secretion (relative scale) Amylin Insulin Glucagon Secreted 0 1 2 3 4 5 6 Co-secreted Glucagon by α-cells Time (hours) by β-cells Meal Level of secretion Glu

Slide 19: Pramlintide (Symlin), an amylin analog, has demonstrated clinical benefits
Pramlintide (Symlin®), an amylin analog, has demonstrated its clinical benefits when associated with insulin and is FDA approved in T1D and T2D Pramlintide pharmacological effects Symlin limitations 1. Activates amylin receptors in different brain areas 1. 3 additional daily injections required on t

Slide 20: Adocia targets to replace insulin by bi-hormonal insulin therapies
Adocia targets to replace insulin by bi-hormonal insulin therapies Medical Multi-hormonal Insulin/Pramlintide is the first prandial benefits combinations insulin able to improve: M1Pram, BC LisPram HbA1c Time-in-Range Ultra-Rapid Insulins Weight loss BC Lispro, Fiasp®, Lyumjev® Well-being Ra

Slide 21: One formulation for pen and one for pump
Adocia is developing one formulation for pen and one for pump Type Pré-clinique Phase I Phase II Phase III Upcoming Regular insulin Pramlintide Clinical Q2 2022 M1Pram POC Ph2 in T1D results in Pen (MDI) communication Rapid insulin Pramlintide Q3 2022 BC LisPram Ph1 T1D pump study results in Pump MD

Slide 22: Promising Phase 1b results of M1Pram in pen vs Novolog
Promising Phase 1b results of M1Pram in pen vs Novolog Results of phase 1b part B: 3-week outpatient trial - M1Pram vs. Novolog (n=16; High dose of insulin) Average glycemia Weight Time In Range After 3 weeks only: 164 16,2 0,5 162 0.4 16 Better post-prandial 0 15,8 glycemic control 160 -7 mg/dL 1

Slide 23: M1Pram in pen generates high expectations from KOLs
M1Pram in pen generates high expectations from KOLs ”By mimicking the normal co-secretion of amylin and “This combination has the potential to insulin with meals, this 2-in-1 combination has the finally deliver on the promise of pramlintide potential to address the persisting unmet need for for a la

Slide 24: BC LisPram: the optimal combination for pumps
BC LisPram: the optimal combination for pumps Clinical Proof-of-Concept established at Mc Gill University, Canada, Adocia intends to reproduce A. Haidar POC with its fixed by Dr. Ahmad Haidar combination of Lispro and Pram delivered in one single pump Lispro in one pump vs. Lispro and Pramlintide ad

Slide 25: Immuno-protective scaffold for islets of Langerhans graft for diabetes
Immuno-protective scaffold for islets of Langerhans graft for diabetes Improving pancreatic islets transplant techniques 25

Slide 26: Immuno-protective hydrogel scaffold to protect pancreatic islets transplants
Adocia developed an immuno-protective hydrogel scaffold to protect pancreatic islets transplants Adocia Hydrogel scaffold Transplant Organoid External Islets sourcing (Allogenic/stem-cell) Adocia’s goal is to develop islets transplantation without immunosuppressive treatments 26

Slide 27: Immuno-protective Hydrogel scaffold for islets transplants
Adocia’s immuno-protective Hydrogel scaffold for islets transplants Semipermeable Hydrogel scaffold Islets Allogenic / stem-cell Glucose, oxygen, nutrients… Macrophages Insulin Antibodies Tomorrow, this technology could be applied to any type of stem cells 27

Slide 28: Development achievements
Development achievements Insulin secretion Encapsulated Islets In vitro encapsulation results in response to glucose Naked Islets Simple and cell-friendly process 3G 15G 3G Human islets viable and functional 6 Fast insulin delivery to glucose stimuli Normalized insulin secretion 5 4 In vivo gr

Slide 29: Obesity: personalized multi-hormonal treatment
Obesity Personalized multi-hormonal obesity treatment: a new paradigm “At Adocia, we believe that long lasting victory against obesity will come from the patients – so let’s give them the tools they need” 29

Slide 30: Combinations of diabetes hormones to treat obesity
Combinations of “diabetes” hormones appears to be a revolutionary way to treat obesity Product Class Mean Mean Weight Loss Weight Loss expected Targeted (standalone) (combo) AMYLIN PramExe Amylin analog -7,9%1 -15% Pramlintide Exenatide GLP1-RA - 8%2 Diabetes GLP-1 Obesity BC GluExe Glucagon -7 to -

Slide 31: Biochaperone Glucagon Exenatide (BC GluExe)
Biochaperone® Glucagon Exenatide (BC GluExe) Proof-of-Concept established in obese mice 120 110 100 Saline (vehicle) BC Exenatide* Exenatide “standalone” showed a significant 90 -10% Exenatide -10% weight loss compared to vehicle BW (%) 80 70 -25% BC Glucagon Exenatide*** showed a significant -25% w

Slide 32: Adocia is developing patient-centric treatments
Adocia is developing patient-centric treatments CURRENT PARADIGM ADOCIA’S PARADIGM Long acting GLP-1 RA are being developed to limit the The patient wears a patch-pump number of injections to deliver combinations of short acting hormones However, despite demonstrated efficacy, GLP-1 RA class goes al

Slide 33: Personalize patient experience by offering dose flexibility
Adocia’s innovation is to personalize patient experience by offering dose flexibility n days infusion n days infusion 1 day off Concentration 4x Patient can: • Intensify the treatment by increasing Concentration 2x the dosage to obtain maximum results Concentration 1x • Stop temporarily by switching

Slide 34: Financial & news flow
Financial & news flow ADOCIA f-

Slide 35: News flow
News flow BC Lispro M1Pram Hormonal combinations in obesity • In China (with partner THDB): • Phase 2 study in T1D in MDI • FIH study 2022/2023 Phase 3 start expected in 2022 (Multiple Daily Injection) completed • In USA/EU: Phase 3 launch scheduled in 2022 • Results communication in Cell Therapy Q2

Slide 36: Key financials & shareholder information
Key financials & shareholder information Key financials features1 Shareholder ownership Market information Already received • Listed on Euronext Paris (ADOC) • €85m raised since inception • 7.4m shares outstanding • $120m received from partnership Soula Family • ADR program in the US (ADOCY) 22,0% E

Slide 37: Summary
Summary • Adocia’s projects are based on 3 proprietary technologies: BioChaperone®, AdOral®, AdoShell® • A well-advanced and diversified pipeline with products ready-to-license: • 5 products with clinical proof-of-concept based on its proprietary BioChaperone® platform o BC Lispro is planned to ente

Slide 38: Thank you for your kind interest
Thank you for your kind interest 115 avenue Lacassagne 69003 Lyon – FRANCE Ph.:+33 4 72 610 610 contact@adocia.com
Source: Internet Archive copy of adocia.com
More decks from Adocia SA
Q3 2026 Earnings Presentation19 slides · Nov 2, 2026
Investor Presentation (November 2026)33 slides · November 2026
Investor Presentation (June 2026)43 slides · June 2026
Investor Presentation (March 2026)43 slides · March 2026
Investor Presentation (November 2025)42 slides · November 2025
Shareholder Meeting (June 2025)85 slides · Jun 11, 2025